CAR T-cell therapy for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new CAR T-cell therapy made from your own immune cells to treat advanced cancers that have not responded to other treatments. It may be an option if your tumor has a specific target and you are otherwise healthy enough.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your cancer is advanced or has spread and has not improved after standard treatments.
- Your tumor has been tested and found to have a specific marker (target) that the therapy attacks.
- You are in generally good health (able to do daily activities, no major organ problems).
- You have not had a gene therapy using a lentivirus before.
- You do not have an active serious infection or autoimmune disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR-T therapy designed to target specific proteins on cancer cells. It may be an option for people with advanced blood cancers (like multiple myeloma or lymphoma) or solid tumors (like small cell lung cancer) that have not responded to other treatments.
This trial tests a new type of immune cell therapy (NKG2D CAR-T cells) for people with advanced solid tumors that have not responded to standard treatments. It aims to see if these specially engineered cells can shrink tumors or slow their growth.
This trial tests IMC001, a new type of immune cell therapy designed to fight advanced solid cancers that have stopped responding to standard treatments. The therapy uses your own immune cells engineered to recognize and attack cancer cells.
This Phase 1/2 trial tests a lab-made immune therapy (CAR-T) designed to attack cancers that have a protein called CD70. It may help people whose solid tumor has not responded to standard treatment, but it also requires specific lab confirmation and careful health screening.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target two markers on cancer cells at once. The goal is to help patients with advanced solid tumors where standard treatments have stopped working or aren't an option.
This trial tests a new type of immune cell (CAR T) made from healthy donors to fight solid tumors that have not responded to other treatments. It may be an option for people with certain cancers that show a protein called PD-L1.
Hear when a new Advanced Malignant Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.